Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different

TB, HIV, and hepatitis C virus (HCV) share a global presence and propensity to disproportionately affect marginalized populations. However, over recent decades, many fewer drugs have been brought to market for TB than for the others.